title: Six-months of recombinant human GH therapy in patients with ischemic cardiac failure.
abstract: Growth hormone therapy in patients with idiopathic dilated cardiomyopathy and ischemic cardiac failure has revealed varying effects on systolic function, probably related to the response in serum insulin-like growth factor I (IGF-I) levels. As diastolic function has not been studied thoroughly, we studied the effects of 6 months of recombinant human growth hormone (rh GH) treatment on systolic and diastolic function in patients with ischemic cardiac failure, using cardiovascular magnetic resonance (MR) imaging. Nineteen patients with ischemic cardiac failure (left ventricular ejection fraction (LVEF), <40%) were studied in a randomized trial. Nine patients received 6 months treatment with growth hormone (2 IU/day). Systolic and diastolic function were assessed at baseline and after 26 weeks by cardiovascular MR imaging. No differences were found in systolic and diastolic function between rh GH treated patients and controls. No change was observed in left ventricular mass index (LVMI), end-diastolic volume, end-systolic-volume and ejection fraction. The treated patients showed no clinical improvement. Six months of treatment with growth hormone therapy in ischemic cardiac failure has no favorable effects on LVMI, on systolic and diastolic function.
authors.affiliation: Department of Endocrinology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands. s.w.van_theil@lumc.nl
authors.forename: Sjoerd W
authors.initials: SW
authors.lastname: van Thiel
authors.forename: Jan W A
authors.initials: JW
authors.lastname: Smit
authors.forename: Albert
authors.initials: A
authors.lastname: de Roos
authors.forename: Jeroen J
authors.initials: JJ
authors.lastname: Bax
authors.forename: Ernst E
authors.initials: EE
authors.lastname: van der Wall
authors.forename: Nienke R
authors.initials: NR
authors.lastname: Biermasz
authors.forename: Eric
authors.initials: E
authors.lastname: Viergever
authors.forename: Hubert W
authors.initials: HW
authors.lastname: Vliegen
authors.forename: Johannes A
authors.initials: JA
authors.lastname: Romijn
authors.forename: Ferdinand
authors.initials: F
authors.lastname: Roelfsema
authors.forename: Hildo J
authors.initials: HJ
authors.lastname: Lamb
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood / Q000187:drug effects; D007334:Insulin-Like Growth Factor I / Q000187:drug effects; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D011994:Recombinant Proteins / Q000627:therapeutic use*; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I